A Phase 1b/2 Open-Label Study of the Efficacy and Safety of Etigilimab (MPH313) Administered in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors (ACTIVATE)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 01 Nov 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Etigilimab (Primary) ; Nivolumab (Primary)
Indications Adenocarcinoma; Carcinoma; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Germ cell and embryonal neoplasms; Germ cell cancer; Head and neck cancer; Liposarcoma; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Sarcoma; Solid tumours; Squamous cell cancer; Uveal melanoma
Focus Therapeutic Use
Acronyms ACTIVATE
Sponsors Mereo BioPharma

21 Feb 2024 Status changed from active, no longer recruiting to completed.
24 Oct 2023 Results (n=76) assessing presented at the 48th European Society for Medical Oncology Congress.
21 Oct 2023 According to a Mereo BioPharma media release, data from this trial presented at the ESMO 2023 Congress

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com